The studies’ findings indicated that ROSE-010 and GLP-1 have prospective therapeutic effects on the management of IBS, particularly in subtypes defined by constipation (IBS-C) and mixed symptoms, as shown in Table 5. The gene discussed is GLP1R; the disease is irritable bowel syndrome.